

Caterina Marchi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8150464/caterina-marchio-publications-by-year.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

148 papers	5,208 citations	39 h-index	68 g-index
162 ext. papers	6,182 ext. citations	6.8 avg, IF	5.27 L-index

#	Paper	IF	Citations
148	Incorporation of TILs in daily breast cancer care: how much evidence can we bear?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022 , 1	5.1	4
147	Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors.. <i>Npj Precision Oncology</i> , 2022 , 6, 15	9.8	0
146	Unusual Patterns of HER2 Expression in Breast Cancer: Insights and Perspectives.. <i>Pathobiology</i> , 2022 , 1-19	3.6	5
145	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022 , 7, 100459	6.4	1
144	"Borderline" epithelial lesions of the breast: what have we learned in the past three decades?. <i>Pathologica</i> , 2021 , 113, 354-359	1.9	0
143	Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥ 0 , HER2 copy number . <i>British Journal of Cancer</i> , 2021 , 124, 1836-1842	8.7	2
142	Personalized therapeutic strategies in HER2-driven gastric cancer. <i>Gastric Cancer</i> , 2021 , 24, 897-912	7.6	1
141	Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors. <i>Cancers</i> , 2021 , 13,	6.6	8
140	Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. <i>Seminars in Cancer Biology</i> , 2021 , 72, 123-135	12.7	35
139	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. <i>Molecular Oncology</i> , 2021 , 15, 1024-1039	7.9	6
138	Optimized EGFR Blockade Strategies in Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021 , 27, 3126-3140	12.9	6
137	Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
136	Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 644737	5.3	18
135	Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients. <i>Cancers</i> , 2021 , 13,	6.6	1
134	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. <i>Modern Pathology</i> , 2021 , 34, 2130-2140	9.8	2
133	Basic principles of biobanking: from biological samples to precision medicine for patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 479, 233-246	5.1	8
132	Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network. <i>Pathologica</i> , 2021 , 113, 262-271	1.9	5

131	Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	3
130	HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 143	22.4	0
129	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. <i>Breast</i> , 2021 , 59, 94-101	3.6	3
128	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 279	12.8	12
127	Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. <i>Journal of Clinical Pathology</i> , 2020 ,	3.9	1
126	Oncogenic properties and signaling basis of the PAX8-GLIS3 fusion gene. <i>International Journal of Cancer</i> , 2020 , 147, 2253-2264	7.5	4
125	Cold Formalin Fixation Guarantees DNA Integrity in Formalin Fixed Paraffin Embedded Tissues: Premises for a Better Quality of Diagnostic and Experimental Pathology With a Specific Impact on Breast Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 173	5.3	5
124	Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer. <i>JAMA Oncology</i> , 2020 , 6, 584-585	13.4	
123	AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells. <i>Cells</i> , 2020 , 9,	7.9	12
122	The Immune Landscape in Women Cancers. <i>Cancer Treatment and Research</i> , 2020 , 180, 215-249	3.5	1
121	Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e12570-e12570	2.2	
120	HER2 in Breast Cancer. <i>Encyclopedia of Pathology</i> , 2020 , 151-161	0	
119	Breast Pathology. <i>Encyclopedia of Pathology</i> , 2020 , 289-293	0	1
118	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6254-6265	12.9	10
117	Reoperation rate after breast conserving surgery as quality indicator in breast cancer treatment: A reappraisal. <i>Breast</i> , 2020 , 53, 181-188	3.6	4
116	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. <i>Modern Pathology</i> , 2020 , 33, 354-366	9.8	17
115	The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas. <i>Pathobiology</i> , 2020 , 87, 125-142	3.42	21
114	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits. <i>Cancer Research</i> , 2019 , 79, 5884-5896	10.1	26

113	Tissues under-vacuum to overcome suboptimal preservation. <i>New Biotechnology</i> , 2019 , 52, 104-109	6.4	6
112	Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study. <i>Histopathology</i> , 2019 , 75, 312-319	7.3	6
111	Assessment of a High Sensitivity Method for Identification of R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients. <i>Cancers</i> , 2019 , 11,	6.6	3
110	Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers. <i>Cell Death and Differentiation</i> , 2019 , 26, 2223-2236	12.7	19
109	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM). <i>Cancers</i> , 2019 , 11,	6.6	11
108	ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. <i>Annals of Oncology</i> , 2019 , 30, 1417-1427	10.3	133
107	PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. <i>Modern Pathology</i> , 2019 , 32, 1734-1743	9.8	18
106	CUTseq is a versatile method for preparing multiplexed DNA sequencing libraries from low-input samples. <i>Nature Communications</i> , 2019 , 10, 4732	17.4	8
105	mutations in metastatic lobular breast cancer patients. <i>Npj Breast Cancer</i> , 2019 , 5, 9	7.8	15
104	The Genomic Landscape of Mucinous Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 737-741	9.7	41
103	Molecular diagnosis in breast cancer. <i>Diagnostic Histopathology</i> , 2018 , 24, 71-82	0.7	3
102	Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 467-475	3.8	3
101	Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine. <i>Pathobiology</i> , 2018 , 85, 23-34	3.6	45
100	Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. <i>Modern Pathology</i> , 2018 , 31, 68-82	9.8	32
99	The expression of LINE1-MET chimeric transcript identifies a subgroup of aggressive breast cancers. <i>International Journal of Cancer</i> , 2018 , 143, 2838-2848	7.5	11
98	Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression. <i>American Journal of Pathology</i> , 2018 , 188, 2378-2391	5.8	6
97	Molecular alterations of neuroendocrine tumours of the lung. <i>Histopathology</i> , 2018 , 72, 142-152	7.3	32
96	RollFISH achieves robust quantification of single-molecule RNA biomarkers in paraffin-embedded tumor tissue samples. <i>Communications Biology</i> , 2018 , 1, 209	6.7	15

95	CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoids – a short report. <i>Cellular Oncology (Dordrecht)</i> , 2018 , 41, 687-691	7.2	2
94	The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment. <i>American Journal of Surgical Pathology</i> , 2018 , 42, 1190-1200	6.7	10
93	High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast. <i>Histopathology</i> , 2018 , 73, 273-283	7.3	25
92	Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. <i>Current Breast Cancer Reports</i> , 2017 , 9, 34-44	0.8	9
91	Genetic analysis of uterine adenomasarcomas and phyllodes tumors of the breast. <i>Molecular Oncology</i> , 2017 , 11, 913-926	7.9	6
90	Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas. <i>Tumor Biology</i> , 2017 , 39, 1010428317694311	2.9	7
89	The expression of GHRH and its receptors in breast carcinomas with apocrine differentiation-further evidence of the presence of a GHRH pathway in these tumors. <i>Human Pathology</i> , 2017 , 64, 164-170	3.7	7
88	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. <i>Histopathology</i> , 2017 , 71, 480-487	7.3	2
87	Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene. <i>British Journal of Cancer</i> , 2017 , 117, 358-366	8.7	7
86	Distinctive pathological and clinical features of lung carcinoids with high proliferation index. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 471, 713-720	5.1	48
85	Enhanced cytotoxic effect of camptothecin nanospheres in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors. <i>Drug Delivery</i> , 2017 , 24, 670-680	7	31
84	The genetic landscape of breast carcinomas with neuroendocrine differentiation. <i>Journal of Pathology</i> , 2017 , 241, 405-419	9.4	35
83	Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2 β Scaffolding Function. <i>Cancer Cell</i> , 2017 , 32, 444-459.e7	24.3	44
82	Acid-free glyoxal as a substitute of formalin for structural and molecular preservation in tissue samples. <i>PLoS ONE</i> , 2017 , 12, e0182965	3.7	14
81	Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017 , 36, 143	12.8	1
80	Classification of pulmonary neuroendocrine tumors: new insights. <i>Translational Lung Cancer Research</i> , 2017 , 6, 513-529	4.4	72
79	Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization. <i>Oncotarget</i> , 2017 , 8, 18680-18698	3.3	15
78	Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. <i>Neuro-Oncology</i> , 2017 , 19, 451-453	1	10

77	Next-generation learning and training: The Cy-TEST experience. <i>Cancer Cytopathology</i> , 2017 , 125, 669-673	39	1
76	Pathology and Molecular Pathology of Breast Cancer 2017 , 173-231		0
75	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. <i>Modern Pathology</i> , 2017 , 30, 69-84	9.8	34
74	The impact of malignant nipple discharge cytology (NDc) in surgical management of breast cancer patients. <i>PLoS ONE</i> , 2017 , 12, e0182073	3.7	4
73	Predictive Diagnostic Pathology in the Target Therapy Era in Breast Cancer. <i>Current Drug Targets</i> , 2017 , 18, 4-12	3	10
72	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. <i>Npj Breast Cancer</i> , 2016 , 2, 16036	7.8	89
71	RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers. <i>European Journal of Cancer</i> , 2016 , 64, 149-58	7.5	4
70	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression. <i>Journal of Pathology</i> , 2016 , 238, 508-18	9.4	80
69	Rediscovering Secondary Tumors of the Prostate in the Molecular Era. <i>Advances in Anatomic Pathology</i> , 2016 , 23, 170-9	5.1	6
68	Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. <i>Npj Breast Cancer</i> , 2016 , 2, 16035	7.8	23
67	BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 4923-4933	12.9	34
66	Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes. <i>Endocrine-Related Cancer</i> , 2016 , 23, 635-50	5.7	5
65	Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues. <i>Laboratory Investigation</i> , 2015 , 95, 561-71	5.9	24
64	PIKING the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. <i>Gynecologic Oncology</i> , 2015 , 137, 321-8	4.9	14
63	The Perfect Pathology Report After Neoadjuvant Therapy. <i>Journal of the National Cancer Institute Monographs</i> , 2015 , 2015, 47-50	4.8	12
62	Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast. <i>Human Pathology</i> , 2015 , 46, 1350-9	3.7	32
61	SF3B1 mutations constitute a novel therapeutic target in breast cancer. <i>Journal of Pathology</i> , 2015 , 235, 571-80	9.4	124
60	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. <i>Journal of Pathology</i> , 2015 , 237, 166-78	9.4	42

59	"Giants in a Microcosm": Multinucleated Giant Cells Populating an Invasive Micropapillary Carcinoma of the Breast. <i>International Journal of Surgical Pathology</i> , 2015 , 23, 654-5	1.2	2
58	MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast. <i>Histopathology</i> , 2015 , 67, 719-29	7.3	68
57	Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification. <i>American Journal of Cancer Research</i> , 2015 , 5, 2212-21	4.4	
56	Current projects in Pre-analytics: where to go?. <i>Recent Results in Cancer Research</i> , 2015 , 199, 65-70	1.5	3
55	Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis. <i>Molecular Cytogenetics</i> , 2014 , 7, 8	2	3 ¹
54	Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. <i>Journal of Pathology</i> , 2014 , 232, 553-65	9.4	75
53	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. <i>Nature Genetics</i> , 2014 , 46, 1166-9	36.3	150
52	Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 511-23	4.4	23
51	Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. <i>Oncogene</i> , 2014 , 33, 619-31	9.2	21
50	Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method. <i>Oncologist</i> , 2014 , 19, 1118-26	5.7	30
49	Well-differentiated neuroendocrine tumour of the breast showing peculiar endovascular spread. <i>Histopathology</i> , 2014 , 64, 597-600	7.3	4
48	Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells. <i>BMC Cancer</i> , 2014 , 14, 922	4.8	15
47	miR-221/222 control luminal breast cancer tumor progression by regulating different targets. <i>Cell Cycle</i> , 2014 , 13, 1811-26	4.7	30
46	Search for neuro-endocrine markers (chromogranin A, synaptophysin and VGF) in breast cancers. An integrated approach using immunohistochemistry and gene expression profiling. <i>Endocrine Pathology</i> , 2014 , 25, 219-28	4.2	11
45	"To be or not to be in a good shape": diagnostic and clinical value of nuclear shape irregularities in thyroid and breast cancer. <i>Advances in Experimental Medicine and Biology</i> , 2014 , 773, 101-21	3.6	16
44	Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. <i>Journal of Pathology</i> , 2013 , 229, 390-9	9.4	16
43	Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues. <i>Frontiers in Oncology</i> , 2013 , 3, 129	5.3	5 ¹
42	Small-cell carcinoma of the breast with squamous differentiation. <i>Histopathology</i> , 2013 , 63, 739-41	7.3	5

41	A collection of primary tissue cultures of tumors from vacuum packed and cooled surgical specimens: a feasibility study. <i>PLoS ONE</i> , 2013 , 8, e75193	3.7	21
40	Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. <i>Histopathology</i> , 2012 , 60, E115-30	7.3	42
39	Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. <i>Histopathology</i> , 2012 , 61, 629-43	7.3	75
38	High-throughput molecular analysis from leftover of fine needle aspiration cytology of mammographically detected breast cancer. <i>Translational Oncology</i> , 2012 , 5, 180-9	4.9	14
37	Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. <i>Journal of Pathology</i> , 2012 , 227, 42-52	9.4	115
36	Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. <i>Endocrine-Related Cancer</i> , 2011 , 18, 565-77	5.7	64
35	Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box. <i>BMC Medicine</i> , 2011 , 9, 41	11.4	33
34	The pathologic complete response open question in primary therapy. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 86-90	4.8	28
33	Breast cancer precursors revisited: molecular features and progression pathways. <i>Histopathology</i> , 2010 , 57, 171-92	7.3	232
32	Chemotherapy with or without trastuzumab. <i>Annals of Oncology</i> , 2010 , 21 Suppl 7, vii112-9	10.3	7
31	Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas). <i>Journal of Clinical Pathology</i> , 2010 , 63, 220-8	3.9	109
30	FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. <i>Cancer Research</i> , 2010 , 70, 2085-94	10.1	533
29	Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study. <i>Modern Pathology</i> , 2010 , 23, 260-9	9.8	19
28	Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. <i>Seminars in Diagnostic Pathology</i> , 2010 , 27, 69-76	4.3	88
27	CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. <i>Breast Cancer Research and Treatment</i> , 2010 , 120, 95-109	4.4	47
26	PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. <i>Clinical Cancer Research</i> , 2009 , 15, 2269-80	12.9	128
25	Tiling path genomic profiling of grade 3 invasive ductal breast cancers. <i>Clinical Cancer Research</i> , 2009 , 15, 2711-22	12.9	138
24	Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. <i>Genes Chromosomes and Cancer</i> , 2009 , 48, 351-65	5	74

23	Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. <i>Journal of Pathology</i> , 2009 , 218, 301-15	9.4	65
22	Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. <i>Journal of Pathology</i> , 2009 , 219, 16-24	9.4	164
21	The role of molecular analysis in breast cancer. <i>Pathology</i> , 2009 , 41, 77-88	1.6	41
20	Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. <i>Laboratory Investigation</i> , 2008 , 88, 491-503	5.9	116
19	ESR1 gene amplification in breast cancer: a common phenomenon?. <i>Nature Genetics</i> , 2008 , 40, 809-10; author reply 810-2	36.3	66
18	Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes. <i>Histopathology</i> , 2008 , 52, 840-6	7.3	69
17	Nestin is expressed in basal-like and triple negative breast cancers. <i>Journal of Clinical Pathology</i> , 2008 , 61, 1045-50	3.9	51
16	Pleomorphism of the nuclear envelope in breast cancer: a new approach to an old problem. <i>Journal of Cellular and Molecular Medicine</i> , 2008 , 12, 209-18	5.6	54
15	Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. <i>Breast Cancer Research and Treatment</i> , 2008 , 111, 27-44	4.4	257
14	Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. <i>Journal of Pathology</i> , 2008 , 215, 398-410	9.4	116
13	The genomic profile of HER2-amplified breast cancers: the influence of ER status. <i>Journal of Pathology</i> , 2008 , 216, 399-407	9.4	69
12	ESR1 amplification in endometrial carcinomas: hope or hyperbole?. <i>Journal of Pathology</i> , 2008 , 216, 271-4.4	4.4	17
11	Molecular diagnosis in breast cancer. <i>Diagnostic Histopathology</i> , 2008 , 14, 202-213	0.7	8
10	Hereditary breast cancer: from molecular pathology to tailored therapies. <i>Journal of Clinical Pathology</i> , 2008 , 61, 1073-82	3.9	35
9	Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. <i>Journal of Clinical Pathology</i> , 2008 , 61, 327-32	3.9	87
8	Traditional urinary cytology and tyrosinase RT-PCR in metastatic melanoma patients: correlation with clinical status. <i>Journal of Clinical Pathology</i> , 2008 , 61, 179-83	3.9	5
7	The expression of Wilms' tumour-1 and Ca125 in invasive micropapillary carcinoma of the breast. <i>Histopathology</i> , 2007 , 51, 824-8	7.3	30
6	Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. <i>Annals of Oncology</i> , 2007 , 18, 1963-8	10.3	9

5	Myxoid renal tumor with myoepithelial differentiation mimicking a salivary gland pleomorphic adenoma: description of a case. <i>American Journal of Surgical Pathology</i> , 2007 , 31, 632-6	6.7	8
4	Evoluzione dell'istopatologia: da flatlandia a una visione a tre dimensioni 2007 , 255-261		
3	A new vision of tubular and tubulo-lobular carcinomas of the breast, as revealed by 3-D modelling. <i>Histopathology</i> , 2006 , 48, 556-62	7.3	18
2	Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006 , 449, 288-96	5.1	66
1	Tissue arrays as fiducial markers for section alignment in 3-D reconstruction technology. <i>Journal of Cellular and Molecular Medicine</i> , 2005 , 9, 438-45	5.6	20